Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 244 | 45% |
| 2020 | 0 | 189 | 51% |
| 2021 | 0 | 176 | 55% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 7 | 386+9.3%/yr | +9.3%/yr | 0.51.1× | 0% | 640 in 2030+8.7%/yr |
| Stroke thrombectomy |
CSF shunts in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Ohio
| 2024 |
| 130 |
| 66% |
| 2025 est. | ≈ 260 | – |
| 2026 est. | ≈ 270 | – |
| 2022 | 0 | 181 | 59% |
| 2023 | 0 | 191 | 63% |
| 2024 | 0 | 130 | 66% |
| 2025 from claims | – | 262 212–308 | 67% |
| 2026 forecast | – | 271 212–340 | 67% |
| 2027 forecast | – | 276 205–365 | 68% |
| 2028 forecast | – | 282 199–389 | 69% |
| 2029 forecast | – | 287 195–411 | 70% |
| 2030 forecast | – | 292 191–434 | 70% |
In 2025, 100% inpatient hospital.
| −3.5%/yr |
| 0.2 |
| 0% |
| 310 in 2030+4.3%/yr |
| Minnesota | 3 | 172+4.2%/yr | +4.2%/yr | 0.4 | 0% | 340 in 2030+12%/yr |
| Missouri | 0 | 137−5.5%/yr | −5.5%/yr | 0.2 | 0% | 180 in 2030+4.6%/yr |
| Wisconsin | 0 | 105+1.8%/yr | +1.8%/yr | 0.2 | 0% | 120 in 2030+2.7%/yr |
| 9 |
| 361−2.8%/yr |
| −2.8%/yr |
| 0.41.1× |
| 0% |
| 360 in 2030−0.1%/yr |
| DBS & VNS | 2 | 246−8.8%/yr | −8.8%/yr | 0.30.8× | 0% | 130 in 2030−10%/yr |
No metro breakdown yet.
Integra LifeSciences leads with 32% of company spending on these surgeons in 2025, +27 pts on 2024.
In 2025, 7 companies reported engagement with Michigan’s surgeons worth $9,200 in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.